Literature DB >> 2504717

Pseudomonas exotoxin: chimeric toxins.

I Pastan1, D FitzGerald.   

Abstract

Pseudomonas exotoxin binds to and enters cells by receptor-mediated endocytosis. Within the cell it requires exposure to low pH to enable it to translocate to the cell cytoplasm where it inhibits protein synthesis by ADP-ribosylating elongation factor 2. The toxin has three main structural domains whose functions are: Ia, cell binding; II, translocation; and III, ADP-ribosylation. Key amino acids have been identified within each domain that are required for the function of the toxin. Chimeric toxins were made originally by using chemical cross-linking reagents to couple Pseudomonas exotoxin (or other toxins) to cell-binding proteins. More recently, a variety of Pseudomonas exotoxin-related chimeric toxins have been made by gene fusion technology. These chimeric toxins may be useful clinically for treating various diseases and experimentally for understanding receptor function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504717

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  25 in total

1.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Microbial "superantigens".

Authors:  M L Misfeldt
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

3.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  The N-terminal part of the enzyme component (C2I) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin.

Authors:  H Barth; F Hofmann; C Olenik; I Just; K Aktories
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

Authors:  Bart E C G de Goeij; Matthias Peipp; Simone de Haij; Edward N van den Brink; Christian Kellner; Thilo Riedl; Rob de Jong; Tom Vink; Kristin Strumane; Wim K Bleeker; Paul W H I Parren
Journal:  MAbs       Date:  2014-01-03       Impact factor: 5.857

6.  Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections.

Authors:  U Brinkmann; J Buchner; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 12.779

7.  Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes.

Authors:  M Ogata; I Pastan; D FitzGerald
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.609

8.  Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice.

Authors:  W Debinski; B Karlsson; L Lindholm; C B Siegall; M C Willingham; D FitzGerald; I Pastan
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 19.456

9.  Characterization of a cellular protease that cleaves Pseudomonas exotoxin.

Authors:  C Fryling; M Ogata; D FitzGerald
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

10.  Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages.

Authors:  Yuko Furusho; Masaaki Miyata; Takami Matsuyama; Taku Nagai; Hua Li; Yuichi Akasaki; Narisato Hamada; Takahiro Miyauchi; Yoshiyuki Ikeda; Takahiro Shirasawa; Kanako Ide; Chuwa Tei
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.